Gagan Harsh Sharma, Managing Director, Bliss GVS Pharma said, "With a population of 145 million, Russia is world's 14th largest pharmaceutical market in terms of volume, with a pre-pandemic annual growth rate of about 8%. At the same time, more than 70% of medicines in the retail market are imported which makes Russia an attractive pharmaceutical export market. Russia being a key member of Eurasian Economic Union, this GMP approval opens the access for Bliss GVS to Russian Pharmaceutical market along with other member CIS countries."
Sharma added, "We intend to launch products in Gynaecology, Urology and Anti-Haemorrhoidal segments across these markets."
On Sensex, Bliss GVS closed at Rs123 per piece down by 3%.